Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure

NCT06413017 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

HCC

Interventions

DRUG: Nimotuzumab
DRUG: ICIs(Immune checkpoint inhibitors)

Sponsor

Tianjin Medical University Cancer Institute and Hospital